Develops drugs for rare bone diseases.
Dec 2025Revenue $500K/yrExpenses $40.6M/yr
No trendCash runway ≈ 1.2 years from Jun 2026
Figures by year
When will Mereo BioPharma Group be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $500K and expenses $40.6M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $500K | $40.6M | −$40.1M |
| Dec 2024 | $0.00 | $47.4M | −$47.4M |
| Dec 2023 | $10.0M | $38.4M | −$28.4M |
| Dec 2022 | $0.00 | $54.4M | −$54.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.